# ECOG-ACRIN Cancer Research Group

Source: https://onco.cc/companies/ecog-acrin/  
OnCo record `ecog-acrin` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

US cooperative group that pairs a therapy group with an imaging group; its E1910 trial moved blinatumomab into frontline leukaemia treatment.

## Summary

Merger (2012) of the Eastern Cooperative Oncology Group and the American College of Radiology Imaging Network. E1910 showed adding blinatumomab consolidation improves survival in MRD-negative B-ALL, leading to the 2024 label. Also runs TMIST (tomosynthesis vs digital mammography screening) and the ECOG performance status scale.

## Fields

- Kind: Company
- Last checked: 2026-09-06
- Also known as: ECOG-ACRIN; Eastern Cooperative Oncology Group; ECOG; American College of Radiology Imaging Network; ACRIN
- Tags: cooperative-group
- HQ: Philadelphia, PA
- Type: cooperative-group
- Website: https://ecog-acrin.org

## Notes

- NCTN cooperative group
- E1910 blinatumomab
- TMIST screening trial
- Imaging biomarker trials

## Sources

- Official website: https://ecog-acrin.org

## Connected records

- drugs: [Blinatumomab](https://onco.cc/drugs/blinatumomab/), [Capecitabine + temozolomide (CAPTEM)](https://onco.cc/drugs/capecitabine-temozolomide/)
- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Melanoma](https://onco.cc/cancers/melanoma/), [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/)
- technologies: [Mammography & tomosynthesis](https://onco.cc/technologies/mammography/)
- institutions: [Montefiore Einstein Comprehensive Cancer Center](https://onco.cc/institutions/montefiore-einstein/), [National Cancer Institute (NIH)](https://onco.cc/institutions/nci/), [University of Wisconsin Carbone Cancer Center](https://onco.cc/institutions/uw-carbone/)
- people: [Mark R. Litzow](https://onco.cc/people/mark-litzow/), [Mitchell D. Schnall](https://onco.cc/people/mitchell-schnall/), [Peter J. O'Dwyer](https://onco.cc/people/peter-odwyer/), [Shaji K. Kumar](https://onco.cc/people/shaji-kumar/)
- trials: [ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)](https://onco.cc/trials/alchemist/), [Bleomycin, Doxycycline, or Talc in Treating Patients With Malignant Pleural Effusions](https://onco.cc/trials/nct00002872/), [CHAARTED (E3805)](https://onco.cc/trials/chaarted/), [ComboMATCH (EAY191)](https://onco.cc/trials/combomatch/), [DREAMseq (ECOG-ACRIN EA6134)](https://onco.cc/trials/dreamseq/), [EA2197 ivonescimab: ivonescimab with gemcitabine and cisplatin versus standard chemo-immunotherapy in advanced biliary tract cancer](https://onco.cc/trials/ea2197-ivonescimab/), [ECOG-ACRIN E1910](https://onco.cc/trials/e1910/), [ECOG-ACRIN E3311](https://onco.cc/trials/ecog-e3311/), [ECOG-ACRIN EA1131](https://onco.cc/trials/ea1131/), [Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer](https://onco.cc/trials/nct00002881/), [I-SPY 1 (CALGB 150007/150012, ACRIN 6657)](https://onco.cc/trials/i-spy-1/), [InPACT](https://onco.cc/trials/inpact/), [InterAACT](https://onco.cc/trials/interaact/), [Lung-MAP (SWOG S1400 and S1900)](https://onco.cc/trials/lung-map/), [NCI-MATCH (EAY131)](https://onco.cc/trials/nci-match/), [OPT-IN (EA2197)](https://onco.cc/trials/opt-in/), [STAMP (EA6174)](https://onco.cc/trials/stamp-merkel/), [TAILORx](https://onco.cc/trials/tailorx/), [Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial](https://onco.cc/trials/nct05863195/), [TMIST (Tomosynthesis Mammographic Imaging Screening Trial)](https://onco.cc/trials/tmist/), [Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging](https://onco.cc/trials/nct04423211/)
- roadmaps: [Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials](https://onco.cc/roadmaps/gallbladder-cancer-roadmap/), [Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on](https://onco.cc/roadmaps/trial-modernisation-roadmap/)
- ideas: [A fixed share of trial-group funding for getting proven care to patients](https://onco.cc/ideas/idea-fund-implementation-quota/), [A national platform trial that every ctDNA-positive patient can join](https://onco.cc/ideas/idea-bio2-national-mrd-platform/), [A publicly held library of investigational drugs available for academic combination trials](https://onco.cc/ideas/idea-tr2-public-combination-formulary/), [Chemotherapy before the second operation for high-risk incidental gallbladder cancer](https://onco.cc/ideas/idea-gbc-neoadjuvant-for-high-risk-incidental-cancer/), [Follow every trial participant for 30 years through registry linkage](https://onco.cc/ideas/idea-data-registry-follow-up-of-trial-participants/)
- key papers: [Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer](https://onco.cc/key-papers/paper-schiller-ecog-1594-four-chemotherapy-regimens-nejm-2002/), [ECOG-ACRIN E1910: adding blinatumomab to chemotherapy for adults with B-cell ALL already in MRD-negative remission](https://onco.cc/key-papers/paper-e1910-blinatumomab-mrd-negative-all-nejm-2024/), [Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer](https://onco.cc/key-papers/paper-sandler-ecog-4599-bevacizumab-nsclc-nejm-2006/)
- bottlenecks: [Older and multimorbid patients are excluded and undertreated](https://onco.cc/bottlenecks/b-aging-comorbidity/), [Secrecy and intellectual property block collaboration](https://onco.cc/bottlenecks/b-ip-collaboration/), [Trials do not represent the people who get cancer](https://onco.cc/bottlenecks/b-trial-diversity/), [Trials enrol too few, too slowly](https://onco.cc/bottlenecks/b-trial-enrolment/)

---
JSON: https://onco.cc/api/v1/entities/ecog-acrin.json